Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial

worldpharmanewsMay 15, 2017

Tag: AstraZeneca , MedImmune , lung cancer

PharmaSources Customer Service